Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 8905 results

  1. Maternal health: promoting maternal health through community based strategies

    Discontinued Reference number: GID-QS10016

    Quality standard
    Discontinued

  2. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued

  3. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

    Safe staffing guideline
    Discontinued

  4. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

    Safe staffing guideline
    Discontinued

  5. Management and organisational approaches to safe staffing

    Discontinued Reference number: GID-SGWAVE0761

    Safe staffing guideline
    Discontinued

  6. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued Reference number: GID-TA10026

    Technology appraisal guidance
    Discontinued

  7. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

    Technology appraisal guidance
    Discontinued

  8. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  9. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  10. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    In development Reference number: GID-TA11647 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  14. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued Reference number: GID-IP1153

    Interventional procedures guidance
    Discontinued

  15. Intravaginal sling for stress urinary incontinence

    Discontinued Reference number: GID-IP267

    Interventional procedures guidance
    Discontinued